Skip to main content

Cancer Chemotherapy and Pharmacology

Ausgabe 3/2013

Inhalt (30 Artikel)

Original Article

A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors

Elisabeth I. Heath, Jeffrey Infante, Lionel D. Lewis, Thehang Luu, Joe Stephenson, Antoinette R. Tan, Saifuddin Kasubhai, Patricia LoRusso, Bo Ma, A. Benjamin Suttle, Joseph F. Kleha, Howard A. Ball, Mohammed M. Dar

Open Access Original Article

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study

Eric Van Den Neste, Bruno Cazin, Ann Janssens, Eva González-Barca, María José Terol, Vincent Levy, Jaime Pérez de Oteyza, Pierre Zachee, Andrew Saunders, Mercè de Frias, Clara Campàs

Original Article

The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels

F. L. Opdam, V. O. Dezentje, J. den Hartigh, A. S. Modak, R. Vree, E. Batman, C. H. Smorenburg, J. W. R. Nortier, H. Gelderblom, H.-J. Guchelaar

Erratum

Erratum to: The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels

F. L. Opdam, V. O. Dezentje, J. den Hartigh, A. S. Modak, R. Vree, E. Batman, C. H. Smorenburg, J. W. R. Nortier, H. Gelderblom, H.-J. Guchelaar

Original Article

Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group

N. Kentepozidis, A. Kotsakis, A. Soultati, S. Agelaki, Ch. Christophylakis, M. Agelidou, L. Chelis, P. Papakotoulas, L. Vamvakas, Z. Zafiriou, G. Samonis, V. Georgoulias

Original Article

Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial

U. O. Njiaju, A. J. Tevaarwerk, K. Kim, J. E. Chang, R. M. Hansen, T. L. Champeny, A. M. Traynor, S. Meadows, L. Van Ummersen, K. Powers, J. A. Stewart

Original Article

Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine

Jessica A. Boyette-Davis, Juan P. Cata, Larry C. Driver, Diane M. Novy, Brian M. Bruel, Deidre L. Mooring, Gwen Wendelschafer-Crabb, William R. Kennedy, Patrick M. Dougherty

Original Article

A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies

John F. Deeken, Rebecca Slack, Glen J. Weiss, Ramesh K. Ramanathan, Michael J. Pishvaian, Jimmy Hwang, Karen Lewandowski, Deepa Subramaniam, Aiwu Ruth He, Ion Cotarla, Aquilur Rahman, John L. Marshall

Original Article

Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells

Samy A. F. Morad, Maria C. Messner, Jonathan C. Levin, Noha Abdelmageed, Hyejung Park, Alfred H. Merrill Jr., Myles C. Cabot

Open Access Original Article

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix

Tadahiro Shoji, Eriko Takatori, Tatsunori Saito, Hideo Omi, Masahiro Kagabu, Fumiharu Miura, Satoshi Takeuchi, Toru Sugiyama

Original Article

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

Robert L. Fine, Anthony P. Gulati, Benjamin A. Krantz, Rebecca A. Moss, Stephen Schreibman, Dawn A. Tsushima, Kelley B. Mowatt, Richard D. Dinnen, Yuehua Mao, Peter D. Stevens, Beth Schrope, John Allendorf, James A. Lee, William H. Sherman, John A. Chabot

Original Article

Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients

V. Ludovini, A. Flacco, F. Bianconi, M. Ragusa, J. Vannucci, G. Bellezza, R. Chiari, V. Minotti, L. Pistola, F. R. Tofanetti, A. Siggillino, E. Baldelli, A. Sidoni, N. Daddi, F. Puma, M. Varella-Garcia, L. Crinò

Open Access Original Article

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors

Géraldine M. Ferron, Yang Dai, Dorothée Semiond

Original Article

Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery

Carlos Pérez-Ruixo, Belén Valenzuela, José Esteban Peris, Pedro Bretcha-Boix, Vanesa Escudero-Ortiz, José Farré-Alegre, Juan José Pérez-Ruixo

Original Article

Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation

Shuji Murakami, Fumihiro Oshita, Makiko Sugiura, Tetsuro Kondo, Haruhiro Saito, Kouzo Yamada

Original Article

(−)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α

Li He, Erying Zhang, Jingli Shi, Xiangyong Li, Keyuan Zhou, Qunzhou Zhang, Anh D. Le, Xudong Tang

Original Article

Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites

Hidenori Tamegai, Teruo Kaiga, Mitsugu Kochi, Masashi Fujii, Noriaki Kanamori, Yoshiaki Mihara, Tomoya Funada, Hiroko Shimizu, Daijo Jinno, Tadatoshi Takayama

Original Article

XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis

Fanghui Ye, Zhenfang Liu, Aihua Tan, Ming Liao, Zengnan Mo, Xiaobo Yang

Original Article

Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609

Tetsuya Taguchi, Daigo Yamamoto, Norikazu Masuda, Koji Oba, Takahiro Nakayama, Takuya Nagata, Masaya Nomura, Katsuhide Yoshidome, Hiroshi Yoshino, Nobuki Matsunami, Masaru Miyashita, Yoshihiko Furuya, Takanori Ishida, Kazuyuki Wakita, Junichi Sakamoto, Shinzaburo Noguchi

Original Article

Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years

Nina E. Kontny, Gudrun Würthwein, Boos Joachim, Alan V. Boddy, Miriam Krischke, Uwe Fuhr, Patrick A. Thompson, Markus Jörger, Jan H. M. Schellens, Georg Hempel

Original Article

Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial

J. L. Welsh, B. A. Wagner, T. J. van’t Erve, P. S. Zehr, D. J. Berg, T. R. Halfdanarson, N. S. Yee, K. L. Bodeker, J. Du, L. J. Roberts II, J. Drisko, M. Levine, G. R. Buettner, J. J. Cullen

Original Article

p75NTR: an enhancer of fenretinide toxicity in neuroblastoma

Veena Ganeshan, John Ashton, Nina F. Schor

Original Article

A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker

Masahiro Hirakawa, Yasushi Sato, Hiroyuki Ohnuma, Tetsuji Takayama, Tamotsu Sagawa, Takayuki Nobuoka, Keisuke Harada, Hiroshi Miyamoto, Yasuhiro Sato, Yasuo Takahashi, Shinich Katsuki, Michiaki Hirayama, Minoru Takahashi, Michihiro Ono, Masahiro Maeda, Kohichi Takada, Tsuyoshi Hayashi, Tsutomu Sato, Koji Miyanishi, Rishu Takimoto, Masayoshi Kobune, Koichi Hirata, Junji Kato

Original Article

Immunogenicity and toxicity of transferrin receptor-targeted hybrid peptide as a potent anticancer agent

Megumi Kawamoto, Masayuki Kohno, Tomohisa Horibe, Koji Kawakami

Short Communication

The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts

Robert A. Forrest, Lonnie P. Swift, Benny J. Evison, Ada Rephaeli, Abraham Nudelman, Don R. Phillips, Suzanne M. Cutts

Short Communication

Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy

Lee Cheng Phua, Mainak Mal, Poh Koon Koh, Peh Yean Cheah, Eric Chun Yong Chan, Han Kiat Ho

Short Communication

Immunohistochemical study of MRP5 expression in meningiomas

George A. Alexiou, Ann Goussia, Antigoni Ntoulia, Panagiota Zagorianakou, Vasiliki Malamou-Mitsi, Spyridon Voulgaris, Athanasios P. Kyritsis

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.